

Screening analysis for drugs of abuse by LC-MS/MS enables fast polarity switching MRM triggered product ion scanning on the fly

# ASMS 2012 MP24-591

Keiko Kudo<sup>1</sup>; Toshikazu Minohata<sup>2</sup>; Junko Iida<sup>2</sup>; Hitoshi Tsuchihashi<sup>3</sup>; Kiochi Suzuki<sup>3</sup>; Kei Zaitsu<sup>4</sup>; Noriaki Shima<sup>4</sup>; Munehiro Katagi<sup>4</sup>; Noriaki Ikeda<sup>1</sup> <sup>1</sup>Kyushu University, Fukuoka, Japan; <sup>2</sup>Shimadzu Corporation, Kyoto, Japan; <sup>3</sup>Osaka Medical Collage, Takatsuki, Japan; <sup>4</sup>Osaka Prefectural Police, Osaka, Japan

# Introduction

In recent years the need for forensic, toxicological and clinical analyses have increased, and as a consequence of sample complexity, analysis has become increasingly challenging due to a growing trend in the use of illicit drugs and non-medicinal prescription drugs. Screening applications requires rapid and unambiguous results that can be achieved using a generic analysis method designed for a large number of target compounds. To meet this need, a universal high speed MRM triggered product ion scanning method with fast polarity switching was applied to simultaneously screen, quantitate and confirm by reference to an MS/MS data base containing the majority of drugs of abuse available in Japan.

# Materials and Methods

[Abused Drugs]

Amphetamine Benzoyl ecgonine Cocaine Codeine Dihydrocodeine Ecgonine methyl ester Ephedrine Ketamine MDA MDMA Methamphetamine Methylephedrine Methylphenidate Morphine Sildenafil THC THC-COOH [Psychotropic Drugs] Amitriptyline

Amoxapine Aripiprazole Chlorpromazine Clomipramine Dosulepin Fluvoxamine Haloperidol Imipramine Levomepromazine Maprotiline Mianserin Mirtazapine Nortriptyline Olanzapine Paroxetine Promethazine Quetiapine Risperidone Sertraline Sulpiride Trazodone Zotepine

[Hypnotic Drugs] 7-Aminoflunitrazepam 7-Aminonimetazepam 7-Aminonitrazepam 8-Hydroxyetizolam Allylisopropylacetylurea alpha-Hydroxybrotizolam alpha-Hydroxytriazolam Alprazolam Amobarbital (neg) Barbital (neg) Bromazepam Bromovalerylurea Brotizolam Diazepam desmethyldiazepam Estazolam Ethyl loflazepate Etizolam Flunitrazepam Flurazepam Hydroxyzine Lorazepam Lormetazepam Midazolam Nimetazepam Nitrazepam Oxazepam Pentobarbital (neg) Phenobarbital (neg) Ouazepam Temazepam Thiamylal (neg) Triazolam Zolpidem Zopiclone

Table 1 List of compounds for Forensic method

[Medical Drugs] Acetaminophen Acetylpheneturide Atropine Biperiden Bupivacaine Carbamazepin Chlorpheniramine Clonazepam Dextromethorphan Diclofenac Diltiazem Diphenhydramine Diprophyline Ethenzamide Glibenclamide Glimepiride Ibuprofen (neg) Lidocaine Loxoprofen (neg) Menivacaine Mexiletine Pancuronium Pentazocine Salicylic\_acid (neg) Trihexyphenidyl Vecuronium Warfarin [Pesticides] Diquat Fenitrothion (MEP) Glufosinate Malathion Methomyl Paraquat [Natural Toxines] Aconitine Colchicine Tetrodotoxin

Samples were analyzed using a Nexera UHPLC system coupled to a LCMS-8030 triple quadrupole mass spectrometer (Shimadzu Corporation, Japan) with LC/MS/MS Method Package for Forensic Toxicology. Database contains product ion scan spectra for 286 forensic and toxicology-related compounds such as 87 Abused drugs, 105 Psychotropic drugs, 70 Hypnotic drugs and others. This library provides Synchronized Survey Scan parameters (product ion spectral data acquisition parameters based on the MRM intensity as threshold) optimized for screening analysis. The simple quantitative method included the most frequently analyzed 111 components of Abused drugs, Psychotropic drugs and Hypnotic drugs for method validation (Table 1).

Samples were separated using a Shim-pack FC-ODS using a gradient elution with ammonium formate and methanol.

### Analytical Conditions

HPLC (Nexera UHPLC system)		Mass (LCMS-8030 triple quadrupole mass spectrometry)		
Column	: Shim-pack FC-ODS (2.0 mml.D. x 150 mmL., 3 um)	Ionization	: ESI	
Mobile Phase A	: 10 mM ammonium formate	Polarity	: Positive & Negative	
Mobile Phase B	: Methanol	Probe Voltage	: +4.5 kV (ESI-Positive mode);	
Gradient Program	: 5%B (0 min) - 95%B (15-20 min) - 5%B (20.01 - 30 min)		-3.5 kV (ESI-Negative mode)	
Flow Rate	: 0.3 mL / min	Nebulizing Gas Flow	w : 1.5 L / min	
Column Temperature	: 40°C	Drying Gas Pressur	e:10 L / min	
Injection Volume	: 5 uL	DL Temperature	: 250°C	
		BH Temperature	: 400°C	

Analysis of several drugs was performed using fast polarity switching and high speed data acquisition LC/MS/MS. This was achieved using Synchronized Survey Scan<sup>®</sup> which refers to the execution of MS/MS scanning triggered by survey scan signals (in this case, MRM). Therefore, during the elution of a peak in MRM analysis, a full-product ion mass spectrum can also be obtained.

Туре	Event#	+/-	Compound Name m/z	Time (0.000 min - 15.050 min) 🔺
MRM	23	+	017_Lidocaine 235.00>86.10	
- Product Ion Scan	24	+	017_Lidocaine 100.00 > 50.00:245.0	) Bositivo
MRM	25	+	012_Aconitine 646.00>104.95	rositive
- Product Ion Scan	26	+	012_Aconitine 100.00 > 50.00:656.0	
MRM	41	-	007_Pentobarbital (neg) 225.15>42.	
- Product Ion Scan	42	-	007_Pentobarbital (neg) 100.00 > 5	5 Negative
MRM	43	-	003_Amobarbital (neg) 225.15>42.0	
- Product Ion Scan	44	-	003_Amobarbital (neg) 100.00 > 50	).
MRM	27	+	024_Vecuronium 557.50>100.10	
- Product Ion Scan	28	+	024_Vecuronium 100.00 > 50.00:56	

#### MRM parameter

#### Product Ion Scan parameter

internet in the second	Finited for Son
Ch. Precurator m/z Product m/z Dentil Time (more)/QL Pre Base(V) Cl. Q3 Pre Base(V) Use for Su = 100   Ch. 08:00 90:00 -120 -220 -218 -218   Ch. 09:00 90:00 -120 -220 -218 -218   Ch. 09:00 -120 -220 -218 -218 -218	Zhet tuli: 00.00 Egit tuli: 98.00 Frezzeng kan niji: 00.00 Galese Breger 15.0 e
Egent Ten: 0.012 mic Og Emolution (unt 💌 Athenoid Settings) Og Emolution (une 💌	Scan Speed. 1577 ulter: Synck Train. 100 and 02 Seaschare. Une
17 taan as bay-ny brentbrong fivent Settengs Dependent Brent:braduct Ian Scan656	gependent Coest Settings

Fig. 1 User Interface of MRM-Product Ion Scan setting at LabSolutions software.

Screening analysis for drugs of abuse by LC-MS/MS enables fast polarity switching MRM triggered product ion scanning on the fly

## Results MS/MS Library Matching

MRM chromatograms of four compounds (each 1000 ng/mL) spiked into urine and analyzed by Nexera coupled to LCMS-8030 following sample preparation (Fig. 2). These product ion scans were searched against the MS/MS library and the four previously identified peaks were assigned a high hit score. The assay generates both MRM and Product lon Scan data (MS/MS) due to the speed of data acquisition

from the LC/MS/MS system. This results in quantitative data and library searching / product matching data to help with product ion confirmation. Fast polarity switching helps to provide information rich product ion spectra resulting in better detection and identification for each compound



Fig. 2 MRM - Product Ion Scan screening data about 4 compounds.

### Simple Quantitative Method for Forensic analyses

Based on the chromatogram obtained by injection of a fixed volume of individual reference standard solutions, the ratio of peak area of the reference standard was calculated and compared to that of the internal standard (Diazepam-d5). The resulting calibration curve was prepared by plotting the ratios of the amount of the reference standard to that of the internal standard. 1st coefficient and intersection were calculated from the calibration curve and were registered to the LCMS method (Fig. 3).

The method was validated using 12 of 111 compounds, between 0,05 ng/mL and 5 ng/mL, spiked into whole blood and treated with solid phase extraction (Table 2). The results from this method indicated a high quantitative performance and could prove useful as rapid confirmation and simple quantitative analysis.





Tahlo 7 Tho calc	rulated results of 12	compounds in y	vhole blood using l	$C_MS/MS(n-2)$ average)
		compounds in v	whole blood using i	-c momentum (n-z average).

		0.05 ng/uL		0.5 ng/uL		5 ng/uL	
Compounds	R.T	Area	Conc.	Area	Conc.	Area	Conc.
Diazepam-d5 (IS)	12.987	396,803	[0.500]	342,441	[0.500]	77,460	[0.500]
Alprazolam	11.857	114,210	0.038	918,575	0.525	2,497,911	6.72
Aripiprazole	15.592	59,975	0.025	700,323	0.205	7,120,340	3.07
Atropine	7.225	327,992	0.084	3,105,470	0.935	17,445,635	10.92
Brotizolam	11.987	42,175	0.044	325,945	0.502	1,043,787	7.49
Colchicine	9.794	21,970	0.015	159,050	0.270	696,217	3.72
Estazolam	11.464	128,563	0.048	1,078,497	0.639	5,580,490	5.49
Ethyl loflazepate	13.068	85,673	0.028	489,250	0.272	1,012,405	2.68
Etizolam	12.092	73,746	0.032	575,984	0.421	2,519,896	5.67
Flunitrazepam	11.229	77,218	0.060	545,933	0.649	1,816,819	7.12
Haloperidol	12.011	616,938	0.048	5,378,666	0.610	28,654,837	7.10
Risperidone	11.778	783,134	0.038	6,811,884	0.510	30,675,213	6.72
Triazolam	11.728	34,424	0.042	283,935	0.550	746,810	6.78

# Conclusion

- A high speed LC/MS/MS data acquisition system was applied to drug screening in forensic, toxicological and clinical analysis.
- To achieve a highly specific and sensitive detection method in screening and quantitation, an MRM triggered product ion scanning method using a polarity switching speed of 15msec and a scan speed of 15,000u/sec was applied to 111 components including illicit drugs, psychotropics, hypnotics, pesticides and other substances.
- As the MRM acquisition time was very fast, this enabled product ion spectra to be generated in both positive and negative ionization mode which could be matched against a user library of compounds as an automated aid to screening and compound identification.



Shimadzu Corporation www.shimadzu.com/an/

For Research Use Only. Not for use in diagnostic procedures. The content of this publication shall not be reproduced, altered or sold for any commercial purpose without the written approval of Shimadzu. The information contained herein is provided to you "as is" without warranty of any kind including without limitation warranties as to its accuracy or completeness. Shimadzu does not assume any responsibility or liability for any damage, whether direct or indirect, relating to the use of this publication. This publication is based upon the information available to Shimadzu on or before the date of publication, and subject to change without notice.

© Shimadzu Corporation, 2012